Company: SNPS
Filing Date: 2025-09-09
Form Type: 10-Q
Source: 0000883241-25-000024
Chunk: 54

Company: SYNOPSYS INC
Filing Date: 2025-09-09
Form: 10-Q
Item: Item 1
Chunk 54
---
972 U.S. Treasury, agency & T-bills7,984 1 — — 7,985 Total:$877,956 $1 $— $— $877,957 Short-term investments:U.S. Treasury, agency & T-bills$19,411 $44 $(6)$— $19,449 Corporate debt securities105,024 349 (115)(2)105,256 Asset-backed securities29,061 130 (7)(20)29,164 Total:$153,496 $523 $(128)$(22)$153,869 (1)See Note 9. Fair Value Measurements for further discussion on fair values.Restricted cash. We include amounts generally described as restricted cash in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown in the condensed consolidated statements of cash flows. Restricted cash is primarily associated with office leases and employee loan programs.

19

The following table provides a reconciliation of cash, cash equivalents and restricted cash included in the condensed consolidated balance sheets and the condensed consolidated statements of cash flows:As ofJuly 31, 2025October 31, 2024(in thousands)Cash and cash equivalents$2,526,475 $3,896,532 Restricted cash included in prepaid and other current assets4,717 1,529 Restricted cash included in other long-term assets978 668 Cash, cash equivalents and restricted cash$2,532,170 $3,898,729 Non-marketable equity securities. Our portfolio of non-marketable equity securities consists of strategic investments in privately held companies. During the first quarter of fiscal 2024, we completed the sale of certain strategic investments in privately-held companies. The gain recognized from the sales was $55.1 million and included in other income (expense), net, in our condensed consolidated statements of income. There were no material impairments of non-marketable equity securities during the three and nine months ended July 31, 2025 and 2024.DerivativesWe recognize derivative instruments as either assets or liabilities in the condensed consolidated balance sheets at fair value and provide qualitative and quantitative disclosures about such derivatives. We operate internationally and are exposed to potentially adverse movements in foreign currency exchange and interest rates. We enter into hedges in the form of foreign currency forward contracts to reduce our exposure to foreign currency rate changes on non-functional currency denominated forecasted transactions and balance sheet